Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21507986 | 0.83 | FGFR1 (0.41) | FGFR1FGFR2TAS1R3TAS1R1MAPT | |
| SCHEMBL18713988 | 0.82 | FGFR1 (0.41) | FGFR1FGFR2TAS1R3TAS1R1MAPT | |
| SCHEMBL16574089 | 0.81 | IDO1 (0.42) | MAP4K4L3MBTL1AGPAT2VEGFAFLT1 | |
| SCHEMBL16574107 | 0.80 | FFAR4 (0.39) | MAP4K4L3MBTL1TSHRFFAR4 | |
| SCHEMBL16574076 | 0.79 | BRD4 (0.46) | FGFR1FGFR2MAPTALDH1A1GAA | |
| SCHEMBL16574077 | 0.78 | MAP4K4 (0.40) | MAP4K4L3MBTL1AGPAT2VEGFAFLT1 | |
| SCHEMBL23992671 | 0.77 | MAP4K4 (0.39) | MAP4K4L3MBTL1AGPAT2VEGFAFLT1 | |
| SCHEMBL16574116 | 0.75 | MAP4K4 (0.43) | MAPTALDH1A1MAP4K4L3MBTL1MEN1 | |
| SCHEMBL16574094 | 0.74 | FFAR1 (0.43) | PTGS2MAP4K4TSHRAGPAT2FFAR1 | |
| SCHEMBL6832377 | 0.72 | MAPT (0.41) | FGFR1FGFR2MAPTVEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
| US-9750740-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Kanos Pharmaceuticals, Inc. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| US-9512122-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | KAROS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2016-04-07 | — | — | US | disclosed |
| US-9199994-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | KAROS PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | FGFR1 1173/4885FGFR2 2940/4885TAS1R3 2452/4885 |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | FGFR1 1173/4885FGFR2 2940/4885TAS1R3 2452/4885 |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | FGFR1 1173/4885FGFR2 2940/4885TAS1R3 2452/4885 |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | FGFR1 1173/4885FGFR2 2940/4885TAS1R3 2452/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | FGFR1 1173/4885FGFR2 2940/4885TAS1R3 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.